Solid lipid-based nanocarriers as efficient targeted drug and gene delivery systems

TrAC - Trends in Analytical Chemistry

Volumn 77, Issue , 2016, Pages 100-108

  Ezzati Nazhad Dolatabadi, Jafar ^a   Omidi, Yadollah ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Co delivery; Drug and gene delivery; Lipid based nanocarriers; Nanostructured lipid carriers; Solid lipid nanoparticles

Indexed keywords

BIOCHEMISTRY; BIOCOMPATIBILITY; DRUG INTERACTIONS; GENE TRANSFER; GENES; LIPOSOMES; NANOPARTICLES;

CO DELIVERIES; GENE DELIVERY; NANO-CARRIERS; NANOSTRUCTURED LIPID CARRIERS; SOLID LIPID NANOPARTICLE (SLN);

NANOSYSTEMS;

BOVINE SERUM ALBUMIN; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; CARBON NANOTUBE; CLOZAPINE; CYANOACRYLATE DERIVATIVE; DISTEAROYLPHOSPHATIDYLETHANOLAMINE; DOCETAXEL; DOXORUBICIN; DRUG CARRIER; ENHANCED GREEN FLUORESCENT PROTEIN; ETHANOLAMINE DERIVATIVE; ETOPOSIDE; HYALURONIC ACID; HYDROXYCAMPTOTHECINE; ISOCARBACYCLIN METHYL ESTER; LIPOSOME; MACROGOL STEARATE; MICROSPHERE; NIOSOME; NOSCAPINE; OCTREOTIDE POLYETHYLENE GLYCOL MONOSTEARATE; PACLITAXEL; POLYBUTYLCYANOACRYLATE; POLYSORBATE 80; SMALL INTERFERING RNA; SOLID LIPID NANOPARTICLE; TRANSFERSOME; TRIPALMITIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; BLOOD BRAIN BARRIER; BRAIN MALARIA; CELL PROLIFERATION; CELL SURVIVAL; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG TARGETING; EMULSION; ENDOCYTOSIS; GENE DELIVERY SYSTEM; GLIOMA; HUMAN; HYDROPHILICITY; IC50; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; NANOENCAPSULATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; SOLUBILITY; TUMOR MICROENVIRONMENT;

EID: 84954288627     PISSN: 01659936     EISSN: 18793142     Source Type: Journal    
DOI: 10.1016/j.trac.2015.12.016     Document Type: Review

References (89)

1. Ezzati Nazhad Dolatabadi J., Hamishehkar H., Eskandani M., Valizadeh H. Formulation, characterization and cytotoxicity studies of alendronate sodium-loaded solid lipid nanoparticles. Colloids Surf. B. Biointerfaces 2014, 117:21-28.
2. Ezzati Nazhad Dolatabadi J., Hamishehkar H., Valizadeh H. Development of dry powder inhaler formulation loaded with alendronate solid lipid nanoparticles: solid-state characterization and aerosol dispersion performance. Drug Dev. Ind. Pharm 2015, 41:1431-1437.
3. Rostami E., Kashanian S., Azandaryani A.H., Faramarzi H., Dolatabadi J.E.N., Omidfar K. Drug targeting using solid lipid nanoparticles. Chem. Phys. Lipids 2014, 181:56-61.
4. Miao J., Du Y.Z., Yuan H., Zhang X.G., Hu F.Q. Drug resistance reversal activity of anticancer drug loaded solid lipid nanoparticles in multi-drug resistant cancer cells. Colloids Surf. B. Biointerfaces 2013, 110:74-80.
5. Gaba B., Fazil M., Ali A., Baboota S., Sahni J.K., Ali J. Nanostructured lipid (NLCs) carriers as a bioavailability enhancement tool for oral administration. Drug Deliv 2015, 22:691-700.
6. Puglia C., Offerta A., Carbone C., Bonina F., Pignatello R., Puglisi G. Lipid Nanocarriers (LNC) and their applications in ocular drug delivery. Curr. Med. Chem 2015, 22:1589-1602.
7. Ezzati Nazhad Dolatabadi J., Valizadeh H., Hamishehkar H. Solid lipid nanoparticles as efficient drug and gene delivery systems: recent breakthroughs. Adv. Pharm. Bull 2015, 5:151-159.
8. Fang J.Y., Fang C.L., Liu C.H., Su Y.H. Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur. J. Pharm. Biopharm 2008, 70:633-640.
9. Feng L., Mumper R.J. A critical review of lipid-based nanoparticles for taxane delivery. Cancer Lett 2013, 334:157-175.
10. Pardeshi C., Rajput P., Belgamwar V., Tekade A., Patil G., Chaudhary K., et al. Solid lipid based nanocarriers: an overview. Acta Pharm 2012, 62:433-472.
11. Aditya N.P., Shim M., Lee I., Lee Y., Im M.-H., Ko S. Curcumin and genistein coloaded nanostructured lipid carriers: in vitro digestion and antiprostate cancer activity. J. Agric. Food Chem 2013, 61:1878-1883.
12. Das S., Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech 2011, 12:62-76.
13. Müller R.H., Mäder K., Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur. J. Pharm. Biopharm 2000, 50:161-177.
14. Attama A.A., Müller-Goymann C.C. Effect of beeswax modification on the lipid matrix and solid lipid nanoparticle crystallinity. Colloids Surf. A Physicochem. Eng. Asp 2008, 315:189-195.
15. Madan J., Pandey R.S., Jain V., Katare O.P., Chandra R., Katyal A. Poly (ethylene)-glycol conjugated solid lipid nanoparticles of noscapine improve biological half-life, brain delivery and efficacy in glioblastoma cells. Nanomedicine 2013, 9:492-503.
16. Vaghasiya H., Kumar A., Sawant K. Development of solid lipid nanoparticles based controlled release system for topical delivery of terbinafine hydrochloride. Eur. J. Pharm. Sci 2013, 49:311-322.
17. Patel M., Souto E.B., Singh K.K. Advances in brain drug targeting and delivery: limitations and challenges of solid lipid nanoparticles. Expert Opin. Drug Deliv 2013, 10:889-905.
18. Müller R.H., Radtke M., Wissing S.A. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv. Drug Deliv. Rev 2002, 54(Suppl.):S131-S155.
19. Sanad R.A., Abdelmalak N.S., Elbayoomy T.S., Badawi A.A. Formulation of a novel oxybenzone-loaded nanostructured lipid carriers (NLCs). AAPS PharmSciTech 2010, 11:1684-1694.
20. Olbrich C., Gessner A., Kayser O., Muller R.H. Lipid-drug-conjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug diminazenediaceturate. J. Drug Target 2002, 10:387-396.
21. Olbrich C., Gessner A., Schroder W., Kayser O., Muller R.H. Lipid-drug conjugate nanoparticles of the hydrophilic drug diminazene-cytotoxicity testing and mouse serum adsorption. J. Control. Release 2004, 96:425-435.
22. Joshi M.D., Muller R.H. Lipid nanoparticles for parenteral delivery of actives. Eur. J. Pharm. Biopharm 2009, 71:161-172.
23. Wang M., Thanou M. Targeting nanoparticles to cancer. Pharmacol. Res 2010, 62:90-99.
24. Mussi S.V., Torchilin V.P. Recent trends in the use of lipidic nanoparticles as pharmaceutical carriers for cancer therapy and diagnostics. J. Mater. Chem. B 2013, 1:5201-5209.
25. Omidi Y., Barar J. Targeting tumor microenvironment: crossing tumor interstitial fluid by multifunctional nanomedicines. Bioimpacts 2014, 4:55-67.
26. Barar J., Omidi Y. Dysregulated pH in tumor microenvironment checkmates cancer therapy. Bioimpacts 2013, 3:149-162.
27. van Vlerken L.E., Vyas T.K., Amiji M.M. Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery. Pharm. Res 2007, 24:1405-1414.
28. Wang A.Z., Gu F., Zhang L., Chan J.M., Radovic-Moreno A., Shaikh M.R., et al. Biofunctionalized targeted nanoparticles for therapeutic applications. Expert Opin. Biol. Ther 2008, 8:1063-1070.
29. Torchilin V.P. Multifunctional nanocarriers. Adv. Drug Deliv. Rev 2006, 58:1532-1555.
30. Singh R., Lillard J.W. Nanoparticle-based targeted drug delivery. Exp. Mol. Pathol 2009, 86:215-223.
31. Papahadjopoulos D., Allen T.M., Gabizon A., Mayhew E., Matthay K., Huang S.K., et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. PNAS 1991, 88:11460-11464.
32. Woodle M.C. Sterically stabilized liposome therapeutics. Adv. Drug Deliv. Rev 1995, 16:249-265.
33. Knop K., Hoogenboom R., Fischer D., Schubert U.S. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew. Chem. Int. Ed Engl 2010, 49:6288-6308.
34. Khajavinia A., Varshosaz J., Dehkordi A.J. Targeting etoposide to acute myelogenous leukaemia cells using nanostructured lipid carriers coated with transferrin. Nanotechnology 2012, 23:405101.
35. Kreuter J., Alyautdin R.N., Kharkevich D.A., Ivanov A.A. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res 1995, 674:171-174.
36. Su Z., Niu J., Xiao Y., Ping Q., Sun M., Huang A., et al. Effect of octreotide-polyethylene Glycol(100) monostearate modification on the pharmacokinetics and cellular uptake of nanostructured lipid carrier loaded with hydroxycamptothecine. Mol. Pharm 2011, 8:1641-1651.
37. Liu D., Liu F., Liu Z., Wang L., Zhang N. Tumor specific delivery and therapy by double-targeted nanostructured lipid carriers with anti-VEGFR-2 antibody. Mol. Pharm 2011, 8:2291-2301.
38. Li S., Su Z., Sun M., Xiao Y., Cao F., Huang A., et al. An arginine derivative contained nanostructure lipid carriers with pH-sensitive membranolytic capability for lysosomolytic anti-cancer drug delivery. Int. J. Pharm 2012, 436:248-257.
39. Spada G., Gavini E., Cossu M., Rassu G., Giunchedi P. Solid lipid nanoparticles with and without hydroxypropyl-β-cyclodextrin: a comparative study of nanoparticles designed for colonic drug delivery. Nanotechnology 2012, 23:095101.
40. Blasi P., Schoubben A., Traina G., Manfroni G., Barberini L., Alberti P.F., et al. Lipid nanoparticles for brain targeting III. Long-term stability and in vivo toxicity. Int. J. Pharm 2013, 454:316-323.
41. Martins S.M., Sarmento B., Nunes C., Lúcio M., Reis S., Ferreira D.C. Brain targeting effect of camptothecin-loaded solid lipid nanoparticles in rat after intravenous administration. Eur. J. Pharm. Biopharm 2013, 85:488-502.
42. Hsu S.-H., Wen C.-J., Al-Suwayeh S.A., Chang H.-W., Yen T.-C., Fang J.-Y. Physicochemical characterization and in vivo bioluminescence imaging of nanostructured lipid carriers for targeting the brain: apomorphine as a model drug. Nanotechnology 2010, 21:405101.
43. Yang S., Zhu J., Lu Y., Liang B., Yang C. Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm. Res 1999, 16:751-757.
44. Zara G.P., Cavalli R., Fundaro A., Bargoni A., Caputo O., Gasco M.R. Pharmacokinetics of doxorubicin incorporated in solid lipid nanospheres (SLN). Pharmacol. Res 1999, 40:281-286.
45. Lockman P.R., Oyewumi M.O., Koziara J.M., Roder K.E., Mumper R.J., Allen D.D. Brain uptake of thiamine-coated nanoparticles. J. Control. Release 2003, 93:271-282.
46. Gupta Y., Jain A., Jain S.K. Transferrin-conjugated solid lipid nanoparticles for enhanced delivery of quinine dihydrochloride to the brain. J. Pharm. Pharmacol 2007, 59:935-940.
47. Liu K.-S., Wen C.-J., Yen T.-C., Sung K.C., Ku M.-C., Wang J.-J., et al. Combined strategies of apomorphine diester prodrugs and nanostructured lipid carriers for efficient brain targeting. Nanotechnology 2012, 23:095103.
48. Koziara J.M., Lockman P.R., Allen D.D., Mumper R.J. In situ blood-brain barrier transport of nanoparticles. Pharm. Res 2003, 20:1772-1778.
49. Koziara J.M., Lockman P.R., Allen D.D., Mumper R.J. Paclitaxel nanoparticles for the potential treatment of brain tumors. J. Control. Release 2004, 99:259-269.
50. Lockman P.R., Koziara J., Roder K.E., Paulson J., Abbruscato T.J., Mumper R.J., et al. In vivo and in vitro assessment of baseline blood-brain barrier parameters in the presence of novel nanoparticles. Pharm. Res 2003, 20:705-713.
51. Reddy L., Sharma R., Chuttani K., Mishra A., Murthy R. Etoposide-incorporated tripalmitin nanoparticles with different surface charge: formulation, characterization, radiolabeling, and biodistribution studies. AAPS J. 2004, 6:55-64.
52. Manjunath K., Venkateswarlu V. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J. Control. Release 2005, 107:215-228.
53. Rijcken C.J.F., Hofman J.-W., van Zeeland F., Hennink W.E., van Nostrum C.F. Photosensitiser-loaded biodegradable polymeric micelles: preparation, characterisation and in vitro PDT efficacy. J. Control. Release 2007, 124:144-153.
54. Carrillo C., Sánchez-Hernández N., García-Montoya E., Pérez-Lozano P., Suñé-Negre J.M., Ticó J.R., et al. DNA delivery via cationic solid lipid nanoparticles (SLNs). Eur. J. Pharm. Sci 2013, 49:157-165.
55. Dolatabadi J.E.N., Omidi Y., Losic D. Carbon nanotubes as an advanced drug and gene delivery nanosystem. Curr. Nanosci 2011, 7:297-314.
56. Delgado D., del Pozo-Rodríguez A., Angeles Solinís M., Bartkowiak A., Rodríguez-Gascón A. New gene delivery system based on oligochitosan and solid lipid nanoparticles: 'In vitro' and 'in vivo' evaluation. Eur. J. Pharm. Sci 2013, 50:484-491.
57. Wu N., Ataai M.M. Production of viral vectors for gene therapy applications. Curr. Opin. Biotechnol 2000, 11:205-208.
58. Omidi Y., Hollins A.J., Benboubetra M., Drayton R., Benter I.F., Akhtar S. Toxicogenomics of non-viral vectors for gene therapy: a microarray study of lipofectin- and oligofectamine-induced gene expression changes in human epithelial cells. J. Drug Target 2003, 11:311-323.
59. Omidi Y., Barar J., Akhtar S. Toxicogenomics of cationic lipid-based vectors for gene therapy: impact of microarray technology. Curr. Drug Deliv 2005, 2:429-441.
60. Omidi Y., Hollins A.J., Drayton R.M., Akhtar S. Polypropylenimine dendrimer-induced gene expression changes: the effect of complexation with DNA, dendrimer generation and cell type. J. Drug Target 2005, 13:431-443.
61. Hollins A.J., Omidi Y., Benter I.F., Akhtar S. Toxicogenomics of drug delivery systems: exploiting delivery system-induced changes in target gene expression to enhance siRNA activity. J. Drug Target 2007, 15:83-88.
62. Omidi Y., Barar J., Heidari H.R., Ahmadian S., Yazdi H.A., Akhtar S. Microarray analysis of the toxicogenomics and the genotoxic potential of a cationic lipid-based gene delivery nanosystem in human alveolar epithelial a549 cells. Toxicol. Mech. Methods 2008, 18:369-378.
63. Ahmadian S., Barar J., Saei A.A., Fakhree M.A., Omidi Y. Cellular toxicity of nanogenomedicine in MCF-7 cell line: MTT assay. J. Vis. Exp 2009, 10.3791/1191.
64. Omidi Y., Barar J. Induction of human alveolar epithelial cell growth factor receptors by dendrimeric nanostructures. Int. J. Toxicol 2009, 28:113-122.
65. Nakhlband A., Barar J., Bidmeshkipour A., Heidari H.R., Omidi Y. Bioimpacts of anti epidermal growth factor receptor antisense complexed with polyamidoamine dendrimers in human lung epithelial adenocarcinoma cells. J. Biomed. Nanotechnol 2010, 6:360-369.
66. Kafil V., Omidi Y. Cytotoxic impacts of linear and branched polyethylenimine nanostructures in A431 cells. Bioimpacts 2011, 1:23-30.
67. Barar J., Omidi Y. Intrinsic bio-signature of gene delivery nanocarriers may impair gene therapy goals. Bioimpacts 2013, 3:105-109.
68. Montana G., Bondì M.L., Carrotta R., Picone P., Craparo E.F., San Biagio P.L., et al. Employment of cationic solid-lipid nanoparticles as RNA carriers. Bioconjug. Chem 2007, 18:302-308.
69. Fàbregas A., Sánchez-Hernández N., Ticó J.R., García-Montoya E., Pérez-Lozano P., Suñé-Negre J.M., et al. A new optimized formulation of cationic solid lipid nanoparticles intended for gene delivery: development, characterization and DNA binding efficiency of TCERG1 expression plasmid. Int. J. Pharm 2014, 473:270-279.
70. del Pozo-Rodriguez A., Delgado D., Solinis M.A., Pedraz J.L., Echevarria E., Rodriguez J.M., et al. Solid lipid nanoparticles as potential tools for gene therapy: in vivo protein expression after intravenous administration. Int. J. Pharm 2010, 385:157-162.
71. Yu W., Liu C., Liu Y., Zhang N., Xu W. Mannan-modified solid lipid nanoparticles for targeted gene delivery to alveolar macrophages. Pharm. Res 2010, 27:1584-1596.
72. Apaolaza P.S., Delgado D., del Pozo-Rodríguez A., Gascón A.R., Solinís M.Á. A novel gene therapy vector based on hyaluronic acid and solid lipid nanoparticles for ocular diseases. Int. J. Pharm 2014, 465:413-426.
73. Ye J., Wang A., Liu C., Chen Z., Zhang N. Anionic solid lipid nanoparticles supported on protamine/DNA complexes. Nanotechnology 2008, 19:285708.
74. Zhang Z., Sha X., Shen A., Wang Y., Sun Z., Gu Z., et al. Polycation nanostructured lipid carrier, a novel nonviral vector constructed with triolein for efficient gene delivery. Biochem. Biophys. Res. Commun 2008, 370:478-482.
75. Castanotto D., Rossi J.J. The promises and pitfalls of RNA-interference-based therapeutics. Nature 2009, 457:426-433.
76. Sheikhi Mehrabadi F., Fischer W., Haag R. Dendritic and lipid-based carriers for gene/siRNA delivery (a review). Curr. Opin. Solid State Mater. Sci 2012, 16:310-322.
77. Ying B., Campbell R.B. Delivery of kinesin spindle protein targeting siRNA in solid lipid nanoparticles to cellular models of tumor vasculature. Biochem. Biophys. Res. Commun 2014, 446:441-447.
78. Jin J., Bae K.H., Yang H., Lee S.J., Kim H., Kim Y., et al. In vivo specific delivery of c-Met siRNA to glioblastoma using cationic solid lipid nanoparticles. Bioconjug. Chem 2011, 22:2568-2572.
79. Landesman-Milo D., Goldsmith M., Leviatan Ben-Arye S., Witenberg B., Brown E., Leibovitch S., et al. Hyaluronan grafted lipid-based nanoparticles as RNAi carriers for cancer cells. Cancer Lett 2013, 334:221-227.
80. Chen J., Liu H., Zhao C., Qin G., Xi G., Li T., et al. One-step reduction and PEGylation of graphene oxide for photothermally controlled drug delivery. Biomaterials 2014, 35:4986-4995.
81. Nakahara T., Kita A., Yamanaka K., Mori M., Amino N., Takeuchi M., et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 2007, 67:8014-8021.
82. Xue H.Y., Wong H.L. Tailoring nanostructured solid-lipid carriers for time-controlled intracellular siRNA kinetics to sustain RNAi-mediated chemosensitization. Biomaterials 2011, 32:2662-2672.
83. Zhang M., Zhou X., Wang B., Yung B.C., Lee L.J., Ghoshal K., et al. Lactosylated gramicidin-based lipid nanoparticles (Lac-GLN) for targeted delivery of anti-miR-155 to hepatocellular carcinoma. J. Control. Release 2013, 168:251-261.
84. Creixell M., Peppas N.A. Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance. Nano Today 2012, 7:367-379.
85. Salvati E., Re F., Sesana S., Cambianica I., Sancini G., Masserini M., et al. Liposomes functionalized to overcome the blood-brain barrier and to target amyloid-beta peptide: the chemical design affects the permeability across an in vitro model. Int. J. Nanomedicine 2013, 8:1749-1758.
86. Chiu R.Y., Tsuji T., Wang S.J., Wang J., Liu C.T., Kamei D.T. Improving the systemic drug delivery efficacy of nanoparticles using a transferrin variant for targeting. J. Control. Release 2014, 180:33-41.
87. Han Y., Zhang Y., Li D., Chen Y., Sun J., Kong F. Transferrin-modified nanostructured lipid carriers as multifunctional nanomedicine for codelivery of DNA and doxorubicin. Int. J. Nanomedicine 2014, 9:4107-4116.
88. Yu Y.H., Kim E., Park D.E., Shim G., Lee S., Kim Y.B., et al. Cationic solid lipid nanoparticles for co-delivery of paclitaxel and siRNA. Eur. J. Pharm. Biopharm 2012, 80:268-273.
89. Taratula O., Kuzmov A., Shah M., Garbuzenko O.B., Minko T. Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. J. Control. Release 2013, 171:349-357.